PTGS2 and lung carcinoma: However, the use of synthetic PPAR agonists, such as rosiglitazone, has been associated with cardiovascular toxicity, due to the downregulation of cyclooxygenase-2 (COX-2) in response to PPAR-γ ligand signaling in lung cancer [56].